🎀 GYN Oncology — 2026-W35

What this page is. Every paper the week's monitor reviewed — including the ones that did not go into the digest. Material marked “Not selected” was reviewed and deliberately left out. It has not been fact-checked to digest standard and is not endorsed. For the curated read, see the digest itself.

Randomized phase 1b/2 trial (OPAL cohort C) in Gynecologic Oncology comparing neoadjuvant niraparib monotherapy versus platinum-taxane chemotherapy in newly diagnosed HRD-positive advanced ovarian cancer. Niraparib produced a lower pre-surgery response rate than chemotherapy, informing whether PARP-inhibitor monotherapy could replace standard neoadjuvant chemotherapy in this population.

Pan-cancer genomic analysis (Clin Cancer Res, elite/Q1) characterizing SMARCA4 alteration classes across tumor types, showing that patients with monoallelic class 2 SMARCA4 alterations and preserved BRG1 benefited from a BRM-degrader phase 1 trial. Suggests a biomarker-defined strategy for selecting patients for BRM-degrader therapy across SMARCA4-altered cancers.

Population-based registry analysis of incidence, mortality, and survival trends in younger women with gynecologic cancers across Nordic countries, published in Gynecologic Oncology. Provides epidemiologic context on rising endometrial cancer rates and improving ovarian cancer survival but has no direct treatment implications.

Narrative review in Crit Rev Oncol Hematol examining how reactive oxygen species regulate ovarian cancer progression, chemoresistance, and ferroptosis susceptibility. Offers a mechanistic framework for understanding platinum/PARP-inhibitor resistance that could inform future therapeutic strategies.

Narrative review in Frontiers in Oncology on multimodal AI approaches (radiomics, histopathology, multi-omics) for predicting outcomes and guiding treatment decisions in high-grade serous ovarian cancer. Highlights the potential of integrated AI models to improve patient stratification, though clinical validation is still emerging.

Real-world validation study in ESMO Open comparing homologous recombination deficiency testing platforms in high-grade serous ovarian cancer samples. Provides technical guidance for standardizing HRD assay cutoffs but does not report clinical outcome correlation, informing lab implementation rather than direct treatment decisions.

Translational analysis of tumor samples from the EORTC 55994 trial (Eur J Cancer) showing that neoadjuvant platinum-based chemotherapy in locally advanced cervical cancer reduces regulatory T-cell infiltration, with less Treg proliferation post-treatment linked to better survival. Exploratory immune-microenvironment findings that may inform future timing of immunotherapy combinations but do not yet guide a specific treatment decision.

Preclinical study (cell lines, organoids, xenografts) in Gynecologic Oncology showing that MAPK-ERK feedback activation drives resistance to trastuzumab deruxtecan in endometrial cancer, and that adding a MEK inhibitor restores sensitivity. Suggests a potential combination strategy to overcome T-DXd resistance, but lacks clinical/patient outcome data.

Nationwide French retrospective cohort study in Oncologist evaluating real-world use of dostarlimab monotherapy in advanced/recurrent dMMR endometrial cancer. Reports less favorable survival outcomes than the pivotal GARNET trial, highlighting a gap between trial and real-world effectiveness.

Multicenter retrospective cohort study in advanced ovarian cancer patients undergoing interval debulking after neoadjuvant chemotherapy, published in Gynecologic Oncology. Refines CT-based prediction models for residual disease and surgical complexity, informing multidisciplinary planning after NACT rather than systemic drug choice.

Multi-center retrospective real-world study of pembrolizumab-based therapy in post-platinum metastatic/recurrent uterine carcinosarcoma, published in International Journal of Gynecological Cancer. Finds an association with improved survival, supporting use of pembrolizumab-based regimens in this setting pending prospective confirmation.

Preclinical translational study in ovarian cancer cell lines and xenografts, published in Oncology Research, showing miR-320e overexpression enhances olaparib sensitivity via PI3K-AKT-mTOR pathway inhibition. Mechanistic findings suggest a potential biomarker/therapeutic strategy to overcome PARP inhibitor resistance but lack clinical outcome validation.

Preclinical xenograft study in Clinical Cancer Research testing an actinium-225-labeled anti-MUC-16 radioimmunoconjugate in ovarian and pancreatic cancer models. Shows durable tumor regression in mouse models, informing future clinical development of MUC-16-targeted radioligand therapy but with no patient data yet.

Preclinical/translational study in Molecular Carcinogenesis identifying FAM3C as a driver of ovarian cancer progression and olaparib resistance via HIF-1α/STAT3 signaling, using cell line and xenograft models. Suggests a potential biomarker and therapeutic target for PARP-inhibitor resistance, but lacks patient-cohort validation linking FAM3C to olaparib outcomes.